Zhitong Finance APP reports that Shandong Jincheng Pharmaceutical Group (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Teir Pharmaceutical Co., Ltd. (referred to as "Jin Cheng Teir"), has received the injection of Chlorpromazine drug registration certificate (Certificate No.: 2024S01517) issued by the State Drug Administration. The injection of Chlorpromazine drug is registered for category four of chemical drugs and, after approval, is considered to have passed the consistency evaluation of quality and efficacy of generic drugs.
According to the website of the State Drug Administration, the relevant formulations of Chlorpromazine currently available in China are injections and tablets, mainly used for short-term treatment of acute moderate pain after surgery.